Among adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma, the phase 2 TRANSCEND FL trial met its primary ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

Researchers Uncover Mechanism That Fuels Growth of Aggressive B-Cell Lymphoma June 18 ... A new detailed analysis of a patient's second cancer after receiving CAR-T therapy for the initial ...

AFTER suffering a fever and losing her voice, mum-of-four Kirsty Lawson thought she was the victim of a nasty winter virus.

A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...

The FIRCE-1 trial investigating the CAR T-cell therapy firi-cel in relapsed/refractory large B-cell lymphoma has been ...

The addition of epcoritamab-bysp to standard chemotherapy significantly improved response and survival for patients with ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...

The FDA has approved Adcetris (brentuximab vedotin) for use in combination with lenalidomide and rituximab to treat patients with relapsed/refractory LBCL after 2 or more lines of systemic therapy who ...

Poor physical performance in patients with non-Hodgkin lymphoma receiving CAR T-cell therapy was linked to worse survival and ...

Although CAR T-cell therapies have been found effective against certain difficult-to-treat malignancies, they are not devoid of safety concerns.

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ...